NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
December 03 2018 - 11:00AM
Business Wire
Novel Trisprcific
CD19.t-haNKTM Natural Killer Cell Therapy
Engineered for Enhanced Tumor Homing for B Cell Lymphoma
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases,
today announced an abstract/poster presentations will be given at
the upcoming 60th Annual Meeting of the American Society of
Hematology (ASH) in San Diego, CA, which runs from December
1-4, 2018.
Presentation Title: Providing a Homing Receptor for CAR
Engineered NK Cells - Improving Cellular Immunotherapy for B-Cell
Lymphoma
Abstract: #4547
Presenter: Nathan Thomas Schomer, Laurent Boissel, Karen
Jiang, Hans Klingemann, John Lee, and Patrick Soon-Shiong,
NantKwest, Inc., Culver City, CA
Date: Monday, December 3, 2018, 6:00-8:00pm
Location: San Diego Convention Center, Hall GH
Presentation Highlights
NantKwest’s proprietary natural killer (NK) therapy is based on
an activated natural killer cell platform (aNK) derived from a
novel cell line with potent cytotoxicity. With over 400 doses
safely administered to over 80 patients across multiple Phase I/II
clinical trials, NantKwest’s off-the-shelf therapies have
demonstrated encouraging clinical responses across a broad range of
cancer cell types.
The company’s haNK® cells, currently in multiple human clinical
trials, have been engineered to carry a high-affinity version of
the CD16/FcγRIII receptor that binds to the Fc portion of a
monoclonal antibody to enhance the cancer cell killing effect when
used in combination with haNK cell therapy.
As part of our next-generation NK cell therapy program, we
further enhanced the potential targeting and homing efficiency of
haNK cell therapy by incorporating both a CD19-targeting CAR,
together with the chemokine-homing receptor, C-C Chemokine Receptor
Type 7 (CCR7), which targets both Chemokine (C-C motif) ligand
CCL19 (CCL19) and Chemokine (C-C motif) ligand 21 (CCL21), key
signaling molecules expressed in lymph nodes to guide homing to
these tissues. This tri-targeting NK cell therapy is designed to
maximize NK cell activity by increasing NK cell migration to tumor
sites and enhance cancer cell killing activity through both
CD19-targeted, CAR-mediated killing, together with antibody
mediated killing when combined with monoclonal clonal antibodies
such as Rituximab.
Dr. Patrick Soon-Shiong, Chairman and CEO of NantKwest
commented, “We look forward to reporting preclinical data on
this novel tri-specific, off-the-shelf, homing CD19.t-haNK cell
therapy. By engineering a novel chemokine-based CAR, into our
off-the-shelf NK cell platform, we show that we can increase NK
cell migration to target cancer cells and this enhanced homing can
potentially maximize NK cell-driven immunogenic cell death.
Representing what we believe will be an attractive treatment
option, we are now focused on transitioning this
next-generation NK cell therapy program to human clinical trials as
rapidly as possible.”
About NantKwest Inc.
NantKwest is an innovative clinical-stage immunotherapy company
focused on harnessing the power of the innate immune system by
using the natural killer cell to treat cancer, infectious diseases
and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer
medicine, with the potential to change the current paradigm of
cancer care. Natural Killer cells are ancient cells in the human
body designed to recognize and detect cells under stress or
infected. The NantKwest “off-the-shelf” activated Natural Killer
(NK) platform has the capacity to destroy cancer and virally
infected cells from the body. The safety of our NK cells as well as
their activity against a broad range of cancers have been tested in
multiple phase 1 clinical trials in the United States, Canada and
Europe. In addition to our NK cells capability to be administered
in the outpatient setting as an “off-the-shelf” living drug, serves
as a universal cell-based therapy without need for individualized
patient matching. Moreover, our NK cell based platform has been
bioengineered to incorporate chimeric antigen receptors (CARs) and
antibody receptors to further optimize targeting and potency in the
therapeutic disease.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying the Company will be successful in improving the treatment
of cancer. Risks and uncertainties related to this endeavor
include, but are not limited to, obtaining FDA approval of our NK
cells as well as other therapeutics as part of the NANT Cancer
Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in
detail in our Securities and Exchange Commission filings, including
in our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2018. These forward-looking statements speak only as
of the date hereof, and we disclaim any obligation to update these
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181203005186/en/
NantKwestMedia Contact:Jen Hodson562-397-3639Jen@nant.com
Investor Contact:David
Pyrce951-551-0949david.pyrce@nantkwest.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024